Immunohistochemical Classification of Primary and Secondary Glioblastomas.
- Author:
Kyu Sang LEE
1
;
Gheeyoung CHOE
;
Kyung Han NAM
;
An Na SEO
;
Sumi YUN
;
Kyung Ju KIM
;
Hwa Jin CHO
;
Sung Hye PARK
Author Information
1. Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Glioblastoma;
Immunohistochemistry;
IDH1 protein, human;
Genes, erbB-1;
Genes, p53
- MeSH:
Antibodies;
Astrocytoma;
Classification*;
Coloring Agents;
Genes, erbB-1;
Genes, p53;
Glioblastoma*;
Humans;
Immunohistochemistry;
Isocitrate Dehydrogenase;
Receptor, Epidermal Growth Factor
- From:Korean Journal of Pathology
2013;47(6):541-548
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Glioblastomas may develop de novo (primary glioblastomas, P-GBLs) or through progression from lower-grade astrocytomas (secondary glioblastomas, S-GBLs). The aim of this study was to compare the immunohistochemical classification of glioblastomas with clinically determined P-GBLs and S-GBLs to identify the best combination of antibodies for immunohistochemical classification. METHODS: We evaluated the immunohistochemical expression of epidermal growth factor receptor (EGFR), p53, and isocitrate dehydrogenase 1 (IDH-1) in 150 glioblastoma cases. RESULTS: According to clinical history, the glioblastomas analyzed in this study consisted of 146 P-GBLs and 4 S-GBLs. Immunohistochemical expression of EGFR, p53, and IDH-1 was observed in 62.6%, 49.3%, and 11.1%, respectively. Immunohistochemical profiles of EGFR(+)/p53(-), IDH-1(-)/EGFR(+)/p53(-), and EGFR(-)/p53(+) were noted in 41.3%, 40.2%, and 28.7%, respectively. Expression of IDH-1 and EGFR(-)/p53(+) was positively correlated with young age. The typical immunohistochemical features of S-GBLs comprised IDH-1(+)/EGFR(-)/p53(+), and were noted in 3.6% of clinically P-GBLs. The combination of IDH-1(-) or EGFR(+) was the best set of immunohistochemical stains for identifying P-GBLs, whereas the combination of IDH-1(+) and EGFR(-) was best for identifying S-GBLs. CONCLUSIONS: We recommend a combination of IDH-1 and EGFR for immunohistochemical classification of glioblastomas. We expect our results to be useful for determining treatment strategies for glioblastoma patients.
